M Rostock1, R Huber, T Greiner, P Fritz, R Scheer, J Schueler, H H Fiebig. 1. Center for Complementary Medicine, Department of Gastroenterology, University Hospital Freiburg, Hugstetter Str. 55, D-79106 Freiburg, Germany. rostock@tumorbio.uni-freiburg.de
Abstract
BACKGROUND: In single case observations, tumour remissions after intratumoral injections of mistletoe extracts have been described. MATERIALS AND METHODS: We investigated the antitumour activity of intratumorally (i.t.)-injected lectin-rich mistletoe extract at different dosages and i.t.-injected mistletoe lectin I in comparison to intravenous (i.v.) Gemcitabine and i.t. treatment with placebo in a human pancreatic cancer xenograft. RESULTS: In a preliminary dose-response experiment, the most marked tumour inhibition was induced when mistletoe extract was given at 8 mg/kg body weight (BW) and mistletoe lectin I at 5.3 microg/kg BW. In a second experiment, bi-weekly i.t. injections of mistletoe extract over 8 weeks resulted in a very high antitumour activity with an optimal T/C value (=median relative tumour volume of the test group vs. the control) of 0.4% combined with 3/8 partial and 3/8 complete remissions. Gemcitabine was less active with 2/8 partial and 1/8 complete remissions and an optimal TIC of 4.6%. CONCLUSION: I.t.-injected lectin-rich mistletoe extract should be further evaluated in patients with inoperable locally advanced pancreatic cancer.
BACKGROUND: In single case observations, tumour remissions after intratumoral injections of mistletoe extracts have been described. MATERIALS AND METHODS: We investigated the antitumour activity of intratumorally (i.t.)-injected lectin-rich mistletoe extract at different dosages and i.t.-injected mistletoe lectin I in comparison to intravenous (i.v.) Gemcitabine and i.t. treatment with placebo in a humanpancreatic cancer xenograft. RESULTS: In a preliminary dose-response experiment, the most marked tumour inhibition was induced when mistletoe extract was given at 8 mg/kg body weight (BW) and mistletoe lectin I at 5.3 microg/kg BW. In a second experiment, bi-weekly i.t. injections of mistletoe extract over 8 weeks resulted in a very high antitumour activity with an optimal T/C value (=median relative tumour volume of the test group vs. the control) of 0.4% combined with 3/8 partial and 3/8 complete remissions. Gemcitabine was less active with 2/8 partial and 1/8 complete remissions and an optimal TIC of 4.6%. CONCLUSION: I.t.-injected lectin-rich mistletoe extract should be further evaluated in patients with inoperable locally advanced pancreatic cancer.
Authors: Roman Huber; Jürgen Eisenbraun; Barbara Miletzki; Michael Adler; Rainer Scheer; Reinhild Klein; Christoph H Gleiter Journal: Eur J Clin Pharmacol Date: 2010-05-14 Impact factor: 2.953
Authors: Katharina Mulsow; Thomas Enzlein; Catharina Delebinski; Sebastian Jaeger; Georg Seifert; Matthias F Melzig Journal: PLoS One Date: 2016-04-18 Impact factor: 3.240
Authors: Rahel Mascha Stammer; Susann Kleinsimon; Jana Rolff; Sebastian Jäger; Angelika Eggert; Georg Seifert; Catharina I Delebinski Journal: J Immunol Res Date: 2017-07-16 Impact factor: 4.818
Authors: Carmen Steinborn; Amy Marisa Klemd; Ann-Sophie Sanchez-Campillo; Sophie Rieger; Marieke Scheffen; Barbara Sauer; Manuel Garcia-Käufer; Konrad Urech; Marie Follo; Annekathrin Ücker; Gunver Sophia Kienle; Roman Huber; Carsten Gründemann Journal: PLoS One Date: 2017-07-18 Impact factor: 3.240
Authors: Christian M Strüh; Sebastian Jäger; Astrid Kersten; Christoph M Schempp; Armin Scheffler; Stefan F Martin Journal: PLoS One Date: 2013-04-17 Impact factor: 3.240